Ventricular volume asymmetry as a risk marker for heart failure and all-cause mortality in transfusion-dependent thalassemia

Abstract

Aim: We measured the left-to-right ventricular volume ratio (LRVR) in a large cohort of patients with transfusion-dependent thalassemia (TDT) and assessed its cross-sectional correlations and its prognostic value in predicting heart failure (HF) and all-cause mortality.

Methods: 1,481 TDT patients underwent cardiovascular magnetic resonance for assessment of biventricular volumes and ejection fractions (cine images) and myocardial iron overload (T2* technique) and for detection of replacement myocardial fibrosis (late gadolinium enhancement-LGE images). The LRVR was defined as the ratio between the left ventricular (LV) and right ventricular (RV) end-diastolic volume indexes.

Results: 1160 (78.3%) patients had normal ventricular symmetry, 220 (14.9%) LV dominant asymmetry (LRVR > 118%), and 101 (6.8%) RV dominant asymmetry (LRVR < 89%).

Cardiac iron levels and LGE were comparable among the three groups. LV dominance was associated with reduced LV function. RV dominance was correlated with aging, reduced RV function, and a history of arrhythmias.

The mean follow-up time was 4.82 ± 2.06 years. HF death occurred in 15 (1.01%) patients. The risk for HF death was significantly higher in the group with RV dominant asymmetry compared to that with normal ventricular symmetry (hazard ratio, HR = 6.07). All-cause death occurred in 42 (2.8%) patients. RV dominant asymmetry was associated with a significantly increased risk of all-cause mortality compared to normal ventricular symmetry [hazard ratios (HR) = 3.57] and LV dominant asymmetry (HR = 6.17). RV dominance remained associated with an increased risk of HF and all-cause mortality even after adjusting for other risk factors such as cardiac iron, LGE, or biventricular ejection fractions.

Conclusion: The LRVR may play a significant role in enhancing death risk stratification in TDT.

Keywords

Transfusion-dependent thalassemia / left-to-right ventricular volume ratio / cardiac magnetic resonance / heart failure mortality / all-cause mortality

References

[1] Galanello R.Beta-thalassemia.Orphanet J Rare Dis2010;5:11 PMCID:PMC2893117

[2] Farmakis D,Taher A,Angastiniotis M.2021 thalassaemia international federation guidelines for the management of transfusion-dependent thalassemia.Hemasphere2022;6:e732 PMCID:PMC9345633

[3] Hentze MW,Andrews NC.Balancing acts: molecular control of mammalian iron metabolism.Cell2004;117:285-97

[4] Rund D.Beta-thalassemia.N Engl J Med2005;353:1135-46

[5] Shah FT,Trompeter S,Piga A.Challenges of blood transfusions in β-thalassemia.Blood Rev2019;37:100588

[6] Modell B,Darlison M,Ingram D.Improved survival of thalassaemia major in the UK and relation to T2* cardiovascular magnetic resonance.J Cardiovasc Magn Reson2008;10:42 PMCID:PMC2563008

[7] Pepe A,Gamberini MR.National networking in rare diseases and reduction of cardiac burden in thalassemia major.Eur Heart J2022;43:2482-92

[8] Anderson LJ,Davis B.Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload.Eur Heart J2001;22:2171-9

[9] Wood JC.Cardiovascular MRI in thalassemia major.Ann N Y Acad Sci2010;1202:173-9

[10] Kirk P,Porter JB.Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major.Circulation2009;120:1961-8 PMCID:PMC2784198

[11] Pepe A,Rossi G.Prediction of cardiac complications for thalassemia major in the widespread cardiac magnetic resonance era: a prospective multicentre study by a multi-parametric approach.Eur Heart J Cardiovasc Imaging2018;19:299-309

[12] Berdoukas V,Moraitis P,Berdoussi E.The efficacy of iron chelator regimes in reducing cardiac and hepatic iron in patients with thalassaemia major: a clinical observational study.J Cardiovasc Magn Reson2009;11:20 PMCID:PMC2713224

[13] Pennell DJ,Cappellini MD.Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with β-thalassemia major.Haematologica2012;97:842-8

[14] Pepe A,Pistoia L.MRI multicentre prospective survey in thalassaemia major patients treated with deferasirox versus deferiprone and desferrioxamine.Br J Haematol2018;183:783-95

[15] Pepe A,Rossi G.Cardiac complications and diabetes in thalassaemia major: a large historical multicentre study.Br J Haematol2013;163:520-7

[16] Albakri A.Iron overload cardiomyopathy: a review of literature on clinical status and meta-analysis of diagnostic and clinical management using iron chelators.Int Med Care2018;2

[17] Kremastinos DT,Theodorakis GN,Toutouzas PK.Myocarditis in beta-thalassemia major. A cause of heart failure.Circulation1995;91:66-71

[18] Pepe A,Capra M.Myocardial scarring by delayed enhancement cardiovascular magnetic resonance in thalassaemia major.Heart2009;95:1688-93

[19] Wood JC.Cardiac complications in thalassemia throughout the lifespan: victories and challenges.Ann N Y Acad Sci2023;1530:64-73 PMCID:PMC10841366

[20] Dahiya A,Jellis C,Wahi S.Echocardiographic assessment of raised pulmonary vascular resistance: application to diagnosis and follow-up of pulmonary hypertension.Heart2010;96:2005-9

[21] Cho IJ,Kwon KH.Effect of anemia correction on left ventricular structure and filling pressure in anemic patients without overt heart disease.Korean J Intern Med2014;29:445-53 PMCID:PMC4101591

[22] Hegde N,Gayomali C.The cardiomyopathy of iron deficiency.Tex Heart Inst J2006;33:340-4

[23] Bellenger NG,Ray SG.Comparison of left ventricular ejection fraction and volumes in heart failure by echocardiography, radionuclide ventriculography and cardiovascular magnetic resonance; are they interchangeable?.Eur Heart J2000;21:1387-96

[24] Puntmann VO,Hinojar R.SCMR Clinical Trial Writing GroupSociety for Cardiovascular Magnetic Resonance (SCMR) expert consensus for CMR imaging endpoints in clinical research: part I - analytical validation and clinical qualification.J Cardiovasc Magn Reson2018;20:67 PMCID:PMC6147157

[25] Ibrahim EH,Baruah D.Value CMR: towards a comprehensive, rapid, cost-effective cardiovascular magnetic resonance imaging.Int J Biomed Imaging2021;2021:8851958

[26] Meloni A,Gamberini MR.Multi-parametric cardiac magnetic resonance for prediction of heart failure death in thalassemia major.Diagnostics2023;13:890 PMCID:PMC10001258

[27] Aimo A,Kasa G.Left-to-right ventricular volume ratio and outcome in heart failure with preserved ejection fraction.J Cardiovasc Med2023;24:552-60

[28] Altmayer SP,Addetia K,Forfia PR.Cardiac MRI right ventricle / left ventricle (RV/LV) volume ratio improves detection of RV enlargement.J Magn Reson Imaging2016;43:1379-85

[29] McCracken C,Abdulelah ZA.Ventricular volume asymmetry as a novel imaging biomarker for disease discrimination and outcome prediction.Eur Heart J Open2024;4:oeae059 PMCID:PMC11306927

[30] Moccia E,Miles CJ.Arrhythmogenic cardiomyopathy and differential diagnosis with physiological right ventricular remodelling in athletes using cardiovascular magnetic resonance.Int J Cardiovasc Imaging2022;38:2723-32

[31] Luijkx T,Prakken NH.Impact of revised task force criteria: distinguishing the athlete’s heart from ARVC/D using cardiac magnetic resonance imaging.Eur J Prev Cardiol2012;19:885-91

[32] Meloni A,Positano V.Evaluation of a web-based network for reproducible T2* MRI assessment of iron overload in thalassemia.Int J Med Inform2009;78:503-12

[33] Ramazzotti A,Positano V.Multicenter validation of the magnetic resonance T2* technique for segmental and global quantification of myocardial iron.J Magn Reson Imaging2009;30:62-8

[34] Meloni A,Missere M.Biventricular reference values by body surface area, age, and gender in a large cohort of well-treated thalassemia major patients without heart damage using a multiparametric CMR approach.J Magn Reson Imaging2021;53:61-70

[35] Marsella M,Meloni A.Cardiac iron and cardiac disease in males and females with transfusion-dependent thalassemia major: a T2* magnetic resonance imaging study.Haematologica2011;96:515-20 PMCID:PMC3069227

[36] Meloni A,Borsellino Z.Different patterns of myocardial iron distribution by whole-heart T2* magnetic resonance as risk markers for heart complications in thalassemia major.Int J Cardiol2014;177:1012-9

[37] Meloni A,Positano V.Single region of interest versus multislice T2* MRI approach for the quantification of hepatic iron overload.J Magn Reson Imaging2011;33:348-55

[38] Cerqueira MD,Dilsizian V.American Heart Association Writing Group on Myocardial Segmentation and Registration for Cardiac ImagingStandardized myocardial segmentation and nomenclature for tomographic imaging of the heart: a statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association.Circulation2002;105:539-42

[39] Wood JC,Ghugre N.MRI R2 and R2^* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients.Blood2005;106:1460-5 PMCID:PMC1895207

[40] Meloni A,Jones A,Lombardi M.The use of appropriate calibration curves corrects for systematic differences in liver R2* values measured using different software packages.Br J Haematol2013;161:888-91 PMCID:PMC3672338

[41] Angelucci E,McLaren CE.Hepatic iron concentration and total body iron stores in thalassemia major.N Engl J Med2000;343:327-31

[42] McDonagh TA,Adamo M.ESC Scientific Document Group2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC.Eur Heart J2021;42:3599-726

[43] Buxton AE,Callans DJ.American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (ACC/AHA/HRS Writing Committee to Develop Data Standards on Electrophysiology)ACC/AHA/HRS 2006 key data elements and definitions for electrophysiological studies and procedures: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (ACC/AHA/HRS Writing Committee to Develop Data Standards on Electrophysiology).Circulation2006;114:2534-70

[44] Cogliandro T,Mancuso L.Society for the Study of Thalassemia and Hemoglobinopathies (SoSTE)Guideline recommendations for heart complications in thalassemia major.J Cardiovasc Med2008;9:515-25

[45] Sayed SZ,Abd El-hakim AEA,Amin AS.The early cardiac involvement in patients with β-thalassemia major.The Egyptian Heart Journal2013;65:243-9

[46] Akiki N,Bou-fakhredin R,Taher AT.Cardiovascular complications in β-Thalassemia: getting to the heart of it.Thalassemia Reports2023;13:38-50

[47] Patel N,Malik P.Placenta growth factor augments endothelin-1 and endothelin-B receptor expression via hypoxia-inducible factor-1α.Blood2008;112:856-65 PMCID:PMC2481529

[48] Meloni A,Pepe A,Coates TD.Pulmonary hypertension in well-transfused thalassemia major patients.Blood Cells Mol Dis2015;54:189-94 PMCID:PMC4297514

[49] d’Humières T,Savale L.Atrial arrhythmia in adults with sickle cell anemia: a missing link toward understanding and preventing strokes.Blood Adv2024;8:5625-38 PMCID:PMC11550361

[50] Gorter TM,Rienstra M.Right heart dysfunction in heart failure with preserved ejection fraction: the impact of atrial fibrillation.J Card Fail2018;24:177-85

[51] Meloni A,Quota A.Prognostic value of multiparametric cardiac magnetic resonance in sickle cell patients.Ann Hematol2023;102:261-70

[52] Altmayer SPL,Addetia K,Forfia PR.Using all-cause mortality to define severe RV dilation with RV/LV volume ratio.Sci Rep2018;8:7200 PMCID:PMC5940893

[53] Bax S,Ahmed R.Right ventricular to left ventricular ratio at CT pulmonary angiogram predicts mortality in interstitial lung disease.Chest2020;157:89-98

[54] Becattini C,Germini F.Computed tomography to assess risk of death in acute pulmonary embolism: a meta-analysis.Eur Respir J2014;43:1678-90

[55] Naeije R.The overloaded right heart and ventricular interdependence.Cardiovasc Res2017;113:1474-85

[56] Kerber RE,Abboud FM.Abnormal motion of the interventricular septum in right ventricular volume overload: experimental and clinical echocardiographic studies.Circulation1973;48:86-96

[57] Arcari L,Altieri S.Longitudinal changes of left and right cardiac structure and function in patients with end-stage renal disease on replacement therapy.Eur J Intern Med2020;78:95-100

[58] Izzy M,Lin G.Cirrhotic Cardiomyopathy ConsortiumRedefining cirrhotic cardiomyopathy for the modern era.Hepatology2020;71:334-45 PMCID:PMC7288530

[59] Jahangir E,Murthy VL.The forgotten right ventricle in cardio-oncology.J Nucl Cardiol2020;27:2164-6 PMCID:PMC6697233

[60] Pena E,El Alam S.Oxidative stress, kinase activity and inflammatory implications in right ventricular hypertrophy and heart failure under hypobaric hypoxia.Int J Mol Sci2020;21:6421 PMCID:PMC7503689

[61] Thandavarayan RA,Guha A.Pathophysiology of acute and chronic right heart failure.Cardiol Clin2020;38:149-60 PMCID:PMC11976311